Article Information
vol. 5 no. 1
PubMed
Published By
Online ISSN
History
- Received March 3, 2018
- Accepted November 13, 2018
- Published online February 1, 2019.
Copyright & Usage
Copyright ©ERS 2019 This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
Author Information
- Helen K. Reddel1,
- Maria Gerhardsson de Verdier2,
- Alvar Agustí3,
- Gary Anderson4,
- Richard Beasley5,
- Elisabeth H. Bel6,
- Christer Janson7,
- Barry Make8,
- Richard J. Martin8,
- Ian Pavord9,
- David Price10,
- Christina Keen11,
- Asparuh Gardev12,
- Stephen Rennard13,
- Alecka Sveréus2,
- Aruna T. Bansal14,
- Lance Brannman15,
- Niklas Karlsson16,
- Javier Nuevo17,
- Fredrik Nyberg18,
- Simon S. Young19 and
- Jørgen Vestbo20
- 1Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia
- 2Respiratory TA, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
- 3Respiratory Institute, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERES, Barcelona, Spain
- 4Lung Health Research Centre, University of Melbourne, Melbourne, Australia
- 5Medical Research Institute of New Zealand, Wellington, New Zealand
- 6Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- 7Dept of Medical Sciences, Uppsala University, Uppsala, Sweden
- 8National Jewish Health and University of Colorado Denver, Denver, CO, USA
- 9Nuffield Dept of Medicine, University of Oxford, Oxford, UK
- 10Observational and Pragmatic Research Institute, Singapore and Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK
- 11Early Clinical Development IMED Biotech Unit, AstraZeneca, Mölndal, Sweden
- 12Global Medical Affairs, AstraZeneca, Cambridge, UK
- 13Early Clinical Development, IMED Biotech Unit, AstraZeneca, Cambridge, UK
- 14Acclarogen Ltd, Cambridge, UK
- 15US Medical Affairs, AstraZeneca, Gaithersberg, MD, USA
- 16Patient Reported Outcomes, Medical Evidence and Observational Research, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
- 17Respiratory TA, Global Medical Affairs, AstraZeneca, Madrid, Spain
- 18Medical Evidence and Observational Research, Global Medical Affairs, AstraZeneca, Mölndal, Sweden
- 19Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK
- 20School of Biological Sciences, University of Manchester, Manchester, UK
- Helen K. Reddel, Woolcock Institute of Medical Research, 431 Glebe Point Road, Glebe, NSW 2037, Australia. E-mail: Helen.reddel{at}sydney.edu.au
Funding
National Institute for Health Research
AstraZeneca
Article usage
Altmetrics
Vol 5 Issue 1
Table of Contents
Prospective observational study in patients with obstructive lung disease: NOVELTY design
